Crizotinib ALK inhibitors

Description Results NMA

PFS 0.49 [0.37; 0.64]

OS 1.02 [0.68; 1.53]

PFS 0.45 [0.34; 0.59] median 10.9 vs. 7.0 mo

OS 0.82 [0.54; 1.25] median NR vs. NR

crizotinib (250 mg) twice daily (n=-9)

vs.

intravenous chemotherapy with either pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter) every 3 weeks (n=-9)

open-label

Parallel groups

Sample size: -9/-9

Primary endpoint: PFS

FU duration:

oral crizotinib, at a dose of 250 mg twice daily (n=172)

vs.

Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin (n=171)

open-label

Sample size: 172/171

Primary endpoint: progression-free survival

FU duration: 16.7 months